ASH1L CRISPR Activation Plasmid (m): sc-431404-ACT
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- ASH1L CRISPR Activation Plasmid (m) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- ASH1L CRISPR Activation Plasmid (m) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by ASH1L CRISPR Activation Plasmid (m) and ASH1L CRISPR Activation Plasmid (m2) target distinct regulatory regions upstream of the Ash1l transcriptional start site. One or both designs may be available
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
ASH1L CRISPR Activation Plasmid (m) | sc-431404-ACT | 20 µg | $397.00 |
Mouse Ash1l encodes ASH1L, a SET-domain histone lysine methyltransferase that functions as a Trithorax group regulator of chromatin accessibility and transcriptional memory during development. ASH1L activity is linked to H3K36 methylation and antagonism of Polycomb-mediated repression, supporting gene expression programs that govern cell fate specification, neuronal differentiation, and synaptic function. Through these epigenetic mechanisms, ASH1L contributes to regulation of transcriptional networks and RNA processing modules important for lineage commitment and maturation. Dysregulation of ASH1L has been associated with neurodevelopmental phenotypes and altered gene-expression states relevant to autism-spectrum and intellectual disability–related research.
ASH1L CRISPR Activation Plasmid (m) provides a targeted, non-destructive approach to upregulating endogenous Ash1l expression without altering the underlying DNA sequence.
ASH1L CRISPR Activation Plasmid (m) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the Ash1l locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the Ash1l transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous ASH1L expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native Ash1l locus and enabling the study of ASH1L-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of ASH1L pathway restoration in tumor cells with silenced or reduced Ash1l expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.